Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc. | 288,000,000 | reported | 02 Mar 2022 | tx 2+288,000,000−288,000,000 |
| Axovant Sciences Ltd. | 89,285,714 | reported | 05 Jun 2018 | tx 1+14,285,714 |
| Adaptive Biotechnologies Corp | 30,993,708 | reported | 11 Nov 2020 | tx 11+36,981,607−41,731,607 |
| Zentalis Pharmaceuticals, Inc. | 4,443,284 | reported | 07 Apr 2020 | tx 1+725,000 |
| Frazier Lifesciences Acquisition Corp | 1,211,582 | reported | 02 Nov 2022 | tx 2+847,062 |
| Arbutus Biopharma Corp | 1,164,000 | reported | 12 Jan 2018 | tx 1+664,000 |
| Roivant Sciences Ltd. | 641,010 | reported | 22 Jun 2023 | tx 4−13,000,000 |
| Inhibrx, Inc. | 511,627 | reported | 28 Aug 2023 | tx 4+2,883,725 |
| 4D Molecular Therapeutics, Inc. | 0 | reported | 15 Dec 2020 | tx 5+3,937,914−2,837,914 |
| Editas Medicine, Inc. | 0 | reported | 08 Feb 2016 | tx 11+5,459,616−8,888,888 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 17 Jun 2024 | SALE | APi Group Corp | 1,912,750 | 38.15 USD | |
| 17 Jun 2024 | SALE | APi Group Corp | 39,032 | 38.15 USD | |
| 17 Jun 2024 | SALE | APi Group Corp | 39,032 | 38.15 USD | |
| 17 Jun 2024 | SALE | APi Group Corp | 1,912,750 | 38.15 USD | |
| 28 Feb 2024 | OTHER | APi Group Corp | 81,300 | 36.90 USD | |
| 28 Feb 2024 | CONVERSION | APi Group Corp | 164,016 | 24.60 USD | |
| 28 Feb 2024 | CONVERSION | APi Group Corp | 8,036,862 | 24.60 USD | |
| 28 Feb 2024 | OTHER | APi Group Corp | 3,983,739 | 36.90 USD | |
| 28 Feb 2024 | CONVERSION | APi Group Corp | 4,000 | 0.00 USD | deriv |
| 28 Feb 2024 | CONVERSION | APi Group Corp | 196,000 | 0.00 USD | deriv |
| 26 Feb 2024 | OTHER | RayzeBio, Inc. | 1,743,556 | — | |
| 26 Feb 2024 | OTHER | RayzeBio, Inc. | 4,899,144 | — | |
| 28 Aug 2023 | PURCHASE | Inhibrx, Inc. | 511,627 | 19.35 USD | |
| 28 Aug 2023 | PURCHASE | Inhibrx, Inc. | 1,038,765 | 19.35 USD | deriv |
| 22 Jun 2023 | SALE | Roivant Sciences Ltd. | 110,756 | 9.90 USD | |
| 22 Jun 2023 | SALE | Roivant Sciences Ltd. | 2,226,195 | 9.90 USD | |
| 22 Jun 2023 | SALE | Roivant Sciences Ltd. | 5,236,006 | 9.90 USD | |
| 22 Jun 2023 | SALE | Roivant Sciences Ltd. | 5,427,043 | 9.90 USD | |
| 02 Nov 2022 | PURCHASE | Frazier Lifesciences Acquisition Corp | 567,532 | 10.08 USD | |
| 02 Nov 2022 | PURCHASE | Frazier Lifesciences Acquisition Corp | 279,530 | 10.08 USD | |
| 07 Oct 2022 | PURCHASE | Inhibrx, Inc. | 333,333 | 30.00 USD | |
| 07 Oct 2022 | PURCHASE | Inhibrx, Inc. | 1,000,000 | 30.00 USD | first after silence |
| 02 Mar 2022 | OTHER | Ginkgo Bioworks Holdings, Inc. | 288,000,000 | — | |
| 02 Mar 2022 | OTHER | Ginkgo Bioworks Holdings, Inc. | 288,000,000 | — | deriv |
| 15 Dec 2020 | CONVERSION | 4D Molecular Therapeutics, Inc. | 2,004,581 | — |
2 purchases reported after at least 12 months of silence — most recent on 07 Oct 2022.